Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma
We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patients were diagnosed with pPCL. The median overall s...
Gespeichert in:
| Veröffentlicht in: | Acta haematologica 2016-01, Vol.135 (2), p.113-121 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 121 |
|---|---|
| container_issue | 2 |
| container_start_page | 113 |
| container_title | Acta haematologica |
| container_volume | 135 |
| creator | Iriuchishima, Hirono Ozaki, Shuji Konishi, Jun Matsumoto, Morio Murayama, Kayoko Nakamura, Fumihiko Yamamoto, Go Handa, Hiroshi Saitoh, Takayuki Nagura, Eiichi Shimizu, Kazuyuki Nojima, Yoshihisa Murakami, Hirokazu |
| description | We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patients were diagnosed with pPCL. The median overall survival (OS) of the pPCL patients was 2.85 years, which was significantly extended compared with that in previous reports. The proportion of patients treated with novel agents was 61%. The OS of the patients treated with novel agents was significantly extended compared with that of patients treated without novel agents according to the generalized Wilcoxon test (2.85 vs. 1.16 years, p = 0.049). This statistical finding suggests that treatment with novel agents could have prevented early death in the patients with pPCL. Age was the only statistically significant prognostic factor associated with an inferior OS (hazard ratio 4.57). Five patients received maintenance therapy with novel agents, and their OS tended to be longer than that of the other patients without maintenance (4.45 vs. 2.85 years). Unlike MM, OS for pPCL has not been improved significantly over the last decade, especially in elderly patients. Therefore, it is important to establish the treatment strategy, particularly after induction treatment. |
| doi_str_mv | 10.1159/000439424 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_439424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1728671001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-d64b8989d47c7342219f5d792cc72071c0b8fd77033886ca747a5d89e6ad6623</originalsourceid><addsrcrecordid>eNo9kE1PwzAMhiMEYmNw4I5QjnAoJGnaJNymaXxpg0nbvcoSdxTadSQt0v49GR07WbYeW34fhC4puaM0UfeEEB4rzvgR6lPOaKTSlB2jfpjTKBGK9dCZ95-hYyJWp6jH0oQkQtI-qmeuqLTb4lmpfaXxCMoST6D9gqrQuFjj5gPw2Glc5_it_oESD1ewbvwDHuJpWzaFCR04PG9au91BO_5Vb_QaPOB5bQpo_ubTLZR1pc_RSa5LDxf7OkCLx_Fi9BxN3p9eRsNJZDhnTWRTvpRKKsuFETFnjKo8sSGJMYIRQQ1ZytwKQeJYytRowYVOrFSQahuyxwN0053duPq7Bd9kVeFNyBb-qlufUcFkKmgwEtDbDjWu9t5Bnm06JRkl2U5vdtAb2Ov92XZZgT2Q_z4DcNUBX9qtwB2A_f4vZ6Z8BA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1728671001</pqid></control><display><type>article</type><title>Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma</title><source>MEDLINE</source><source>Karger_医学期刊</source><creator>Iriuchishima, Hirono ; Ozaki, Shuji ; Konishi, Jun ; Matsumoto, Morio ; Murayama, Kayoko ; Nakamura, Fumihiko ; Yamamoto, Go ; Handa, Hiroshi ; Saitoh, Takayuki ; Nagura, Eiichi ; Shimizu, Kazuyuki ; Nojima, Yoshihisa ; Murakami, Hirokazu</creator><creatorcontrib>Iriuchishima, Hirono ; Ozaki, Shuji ; Konishi, Jun ; Matsumoto, Morio ; Murayama, Kayoko ; Nakamura, Fumihiko ; Yamamoto, Go ; Handa, Hiroshi ; Saitoh, Takayuki ; Nagura, Eiichi ; Shimizu, Kazuyuki ; Nojima, Yoshihisa ; Murakami, Hirokazu</creatorcontrib><description>We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patients were diagnosed with pPCL. The median overall survival (OS) of the pPCL patients was 2.85 years, which was significantly extended compared with that in previous reports. The proportion of patients treated with novel agents was 61%. The OS of the patients treated with novel agents was significantly extended compared with that of patients treated without novel agents according to the generalized Wilcoxon test (2.85 vs. 1.16 years, p = 0.049). This statistical finding suggests that treatment with novel agents could have prevented early death in the patients with pPCL. Age was the only statistically significant prognostic factor associated with an inferior OS (hazard ratio 4.57). Five patients received maintenance therapy with novel agents, and their OS tended to be longer than that of the other patients without maintenance (4.45 vs. 2.85 years). Unlike MM, OS for pPCL has not been improved significantly over the last decade, especially in elderly patients. Therefore, it is important to establish the treatment strategy, particularly after induction treatment.</description><identifier>ISSN: 0001-5792</identifier><identifier>EISSN: 1421-9662</identifier><identifier>DOI: 10.1159/000439424</identifier><identifier>PMID: 26505781</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Disease-Free Survival ; Female ; Humans ; Japan ; Leukemia, Plasma Cell - drug therapy ; Leukemia, Plasma Cell - mortality ; Leukemia, Plasma Cell - therapy ; Male ; Middle Aged ; Multivariate Analysis ; Original Paper ; Prognosis ; Proportional Hazards Models ; Societies, Medical ; Stem Cell Transplantation ; Stem Cells - cytology ; Survival Rate ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Acta haematologica, 2016-01, Vol.135 (2), p.113-121</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>2015 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-d64b8989d47c7342219f5d792cc72071c0b8fd77033886ca747a5d89e6ad6623</citedby><cites>FETCH-LOGICAL-c442t-d64b8989d47c7342219f5d792cc72071c0b8fd77033886ca747a5d89e6ad6623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2422,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26505781$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iriuchishima, Hirono</creatorcontrib><creatorcontrib>Ozaki, Shuji</creatorcontrib><creatorcontrib>Konishi, Jun</creatorcontrib><creatorcontrib>Matsumoto, Morio</creatorcontrib><creatorcontrib>Murayama, Kayoko</creatorcontrib><creatorcontrib>Nakamura, Fumihiko</creatorcontrib><creatorcontrib>Yamamoto, Go</creatorcontrib><creatorcontrib>Handa, Hiroshi</creatorcontrib><creatorcontrib>Saitoh, Takayuki</creatorcontrib><creatorcontrib>Nagura, Eiichi</creatorcontrib><creatorcontrib>Shimizu, Kazuyuki</creatorcontrib><creatorcontrib>Nojima, Yoshihisa</creatorcontrib><creatorcontrib>Murakami, Hirokazu</creatorcontrib><title>Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma</title><title>Acta haematologica</title><addtitle>Acta Haematol</addtitle><description>We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patients were diagnosed with pPCL. The median overall survival (OS) of the pPCL patients was 2.85 years, which was significantly extended compared with that in previous reports. The proportion of patients treated with novel agents was 61%. The OS of the patients treated with novel agents was significantly extended compared with that of patients treated without novel agents according to the generalized Wilcoxon test (2.85 vs. 1.16 years, p = 0.049). This statistical finding suggests that treatment with novel agents could have prevented early death in the patients with pPCL. Age was the only statistically significant prognostic factor associated with an inferior OS (hazard ratio 4.57). Five patients received maintenance therapy with novel agents, and their OS tended to be longer than that of the other patients without maintenance (4.45 vs. 2.85 years). Unlike MM, OS for pPCL has not been improved significantly over the last decade, especially in elderly patients. Therefore, it is important to establish the treatment strategy, particularly after induction treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Japan</subject><subject>Leukemia, Plasma Cell - drug therapy</subject><subject>Leukemia, Plasma Cell - mortality</subject><subject>Leukemia, Plasma Cell - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Original Paper</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Societies, Medical</subject><subject>Stem Cell Transplantation</subject><subject>Stem Cells - cytology</subject><subject>Survival Rate</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>0001-5792</issn><issn>1421-9662</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PwzAMhiMEYmNw4I5QjnAoJGnaJNymaXxpg0nbvcoSdxTadSQt0v49GR07WbYeW34fhC4puaM0UfeEEB4rzvgR6lPOaKTSlB2jfpjTKBGK9dCZ95-hYyJWp6jH0oQkQtI-qmeuqLTb4lmpfaXxCMoST6D9gqrQuFjj5gPw2Glc5_it_oESD1ewbvwDHuJpWzaFCR04PG9au91BO_5Vb_QaPOB5bQpo_ubTLZR1pc_RSa5LDxf7OkCLx_Fi9BxN3p9eRsNJZDhnTWRTvpRKKsuFETFnjKo8sSGJMYIRQQ1ZytwKQeJYytRowYVOrFSQahuyxwN0053duPq7Bd9kVeFNyBb-qlufUcFkKmgwEtDbDjWu9t5Bnm06JRkl2U5vdtAb2Ov92XZZgT2Q_z4DcNUBX9qtwB2A_f4vZ6Z8BA</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Iriuchishima, Hirono</creator><creator>Ozaki, Shuji</creator><creator>Konishi, Jun</creator><creator>Matsumoto, Morio</creator><creator>Murayama, Kayoko</creator><creator>Nakamura, Fumihiko</creator><creator>Yamamoto, Go</creator><creator>Handa, Hiroshi</creator><creator>Saitoh, Takayuki</creator><creator>Nagura, Eiichi</creator><creator>Shimizu, Kazuyuki</creator><creator>Nojima, Yoshihisa</creator><creator>Murakami, Hirokazu</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma</title><author>Iriuchishima, Hirono ; Ozaki, Shuji ; Konishi, Jun ; Matsumoto, Morio ; Murayama, Kayoko ; Nakamura, Fumihiko ; Yamamoto, Go ; Handa, Hiroshi ; Saitoh, Takayuki ; Nagura, Eiichi ; Shimizu, Kazuyuki ; Nojima, Yoshihisa ; Murakami, Hirokazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-d64b8989d47c7342219f5d792cc72071c0b8fd77033886ca747a5d89e6ad6623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Japan</topic><topic>Leukemia, Plasma Cell - drug therapy</topic><topic>Leukemia, Plasma Cell - mortality</topic><topic>Leukemia, Plasma Cell - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Original Paper</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Societies, Medical</topic><topic>Stem Cell Transplantation</topic><topic>Stem Cells - cytology</topic><topic>Survival Rate</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iriuchishima, Hirono</creatorcontrib><creatorcontrib>Ozaki, Shuji</creatorcontrib><creatorcontrib>Konishi, Jun</creatorcontrib><creatorcontrib>Matsumoto, Morio</creatorcontrib><creatorcontrib>Murayama, Kayoko</creatorcontrib><creatorcontrib>Nakamura, Fumihiko</creatorcontrib><creatorcontrib>Yamamoto, Go</creatorcontrib><creatorcontrib>Handa, Hiroshi</creatorcontrib><creatorcontrib>Saitoh, Takayuki</creatorcontrib><creatorcontrib>Nagura, Eiichi</creatorcontrib><creatorcontrib>Shimizu, Kazuyuki</creatorcontrib><creatorcontrib>Nojima, Yoshihisa</creatorcontrib><creatorcontrib>Murakami, Hirokazu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta haematologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iriuchishima, Hirono</au><au>Ozaki, Shuji</au><au>Konishi, Jun</au><au>Matsumoto, Morio</au><au>Murayama, Kayoko</au><au>Nakamura, Fumihiko</au><au>Yamamoto, Go</au><au>Handa, Hiroshi</au><au>Saitoh, Takayuki</au><au>Nagura, Eiichi</au><au>Shimizu, Kazuyuki</au><au>Nojima, Yoshihisa</au><au>Murakami, Hirokazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma</atitle><jtitle>Acta haematologica</jtitle><addtitle>Acta Haematol</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>135</volume><issue>2</issue><spage>113</spage><epage>121</epage><pages>113-121</pages><issn>0001-5792</issn><eissn>1421-9662</eissn><abstract>We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patients were diagnosed with pPCL. The median overall survival (OS) of the pPCL patients was 2.85 years, which was significantly extended compared with that in previous reports. The proportion of patients treated with novel agents was 61%. The OS of the patients treated with novel agents was significantly extended compared with that of patients treated without novel agents according to the generalized Wilcoxon test (2.85 vs. 1.16 years, p = 0.049). This statistical finding suggests that treatment with novel agents could have prevented early death in the patients with pPCL. Age was the only statistically significant prognostic factor associated with an inferior OS (hazard ratio 4.57). Five patients received maintenance therapy with novel agents, and their OS tended to be longer than that of the other patients without maintenance (4.45 vs. 2.85 years). Unlike MM, OS for pPCL has not been improved significantly over the last decade, especially in elderly patients. Therefore, it is important to establish the treatment strategy, particularly after induction treatment.</abstract><cop>Basel, Switzerland</cop><pmid>26505781</pmid><doi>10.1159/000439424</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5792 |
| ispartof | Acta haematologica, 2016-01, Vol.135 (2), p.113-121 |
| issn | 0001-5792 1421-9662 |
| language | eng |
| recordid | cdi_karger_primary_439424 |
| source | MEDLINE; Karger_医学期刊 |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease-Free Survival Female Humans Japan Leukemia, Plasma Cell - drug therapy Leukemia, Plasma Cell - mortality Leukemia, Plasma Cell - therapy Male Middle Aged Multivariate Analysis Original Paper Prognosis Proportional Hazards Models Societies, Medical Stem Cell Transplantation Stem Cells - cytology Survival Rate Transplantation, Autologous Treatment Outcome |
| title | Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T18%3A38%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20Plasma%20Cell%20Leukemia%20in%20the%20Era%20of%20Novel%20Agents:%20A%20Multicenter%20Study%20of%20the%20Japanese%20Society%20of%20Myeloma&rft.jtitle=Acta%20haematologica&rft.au=Iriuchishima,%20Hirono&rft.date=2016-01-01&rft.volume=135&rft.issue=2&rft.spage=113&rft.epage=121&rft.pages=113-121&rft.issn=0001-5792&rft.eissn=1421-9662&rft_id=info:doi/10.1159/000439424&rft_dat=%3Cproquest_karge%3E1728671001%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1728671001&rft_id=info:pmid/26505781&rfr_iscdi=true |